

Noam F PondÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2896212/publications.pdf>

Version: 2024-02-01

14
papers

570
citations

840776

11
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

837
citing authors

#	ARTICLE	IF	CITATIONS
1	Progress in adjuvant systemic therapy for breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 27-44.	27.6	175
2	HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 155-163.	2.5	82
3	Twenty years of anti-HER2 therapy-associated cardiotoxicity. <i>ESMO Open</i> , 2016, 1, e000073.	4.5	76
4	HER2-positive advanced breast cancer treatment in 2020. <i>Cancer Treatment Reviews</i> , 2020, 88, 102033.	7.7	70
5	Adjuvant trastuzumab: a 10-year overview of its benefit. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 61-74.	2.4	40
6	Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 629-649.	2.4	31
7	Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. <i>British Journal of Cancer</i> , 2020, 122, 1453-1460.	6.4	22
8	Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 62, 123-132.	7.7	16
9	Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis. <i>ESMO Open</i> , 2020, 5, e000842.	4.5	16
10	Pertuzumab in HER2-positive early breast cancer: current use and perspectives. <i>Future Oncology</i> , 2019, 15, 1823-1843.	2.4	14
11	Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 181-189.	4.9	13
12	The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). <i>Acta Oncológica</i> , 2020, 59, 723-725.	1.8	7
13	Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer. <i>JCO Global Oncology</i> , 2022, 8, e2100153.	1.8	6
14	Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial. <i>ESMO Open</i> , 2020, 5, e000979.	4.5	2